Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors

Sophie H. Bots, Michelle Schreuder, Jeanine Roeters van Lennep, Sarah Watson, Eugene van Puijenbroek, N. Charlotte Onland-Moret, Hester M. den Ruijter*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)
15 Downloads (Pure)


Sex differences in adverse drug reactions (ADRs) associated with angiotensin-converting enzyme inhibitors (ACEIs) remain poorly understood owing to a lack of sex-specific ADR data from clinical trials.1 Postmarketing pharmacovigilance data, containing structured and detailed ADR information, may play an important role in such analyses. However, these data are often not corrected for prescription numbers and therefore cannot separate sex differences in ADR risk from sex differences in prescription rates. To investigate whether women report more ACEI-related ADRs than men after correction for sex-specific prescription and describe sex differences in reported ADR types, we combined data from the global pharmacovigilance database VigiBase and the prescription-corrected Dutch pharmacovigilance database Lareb.
Original languageEnglish
Pages (from-to)E228224
JournalJAMA network open
Issue number4
Publication statusPublished - 20 Apr 2022

Bibliographical note

Funding Information:
Funding/Support: This work was supported by grant 2020B004 from the Dutch CardioVascular Alliance and European Research Council Consolidator grant 866478.


Dive into the research topics of 'Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors'. Together they form a unique fingerprint.

Cite this